F-box and WD repeat domain containing 9Genealiases: Fbw9 · MEC-15
Q-omics provides the consensus-scored FBXW9 profile across patient tissues and cancer cell-line models. FBXW9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FBXW9 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, FBXW9 protein abundance shows 33,338 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, BLCA, and PDAC as cancer lineages where FBXW9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXW9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXW9 survival associations across molecular data types. FBXW9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXW9 RNA expression–survival associations across cancer types. High FBXW9 expression shows unfavorable associations in ACC, KICH, BLCA and LGG, but favorable associations in READ and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FBXW9 RNA expression.
This table summarizes FBXW9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXW9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXW9 shows lower tumor expression in KICH and higher tumor expression in BLCA, COAD, KIRP, LIHC and STAD. The BLCA box plot shows higher FBXW9 RNA expression in tumor versus normal tissue (log2 FC = +1.497, t-test p < 0.001).
This table shows molecular features associated with FBXW9 in patient tissues and cancer cell lines. In patient samples, FBXW9 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXW9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
